BRCA1/2 mutation and homologous recombination deficiency (HRD) are well-characterized biomarkers to help identify patients who can benefit from Poly (ADP-ribose) polymerase inhibitor (PARPi) and platinum-based chemotherapies. Although US FDA approved two commercial HRD assays as companion diagnostic tests, a relatively low-cost, reliable, and distributed diagnostic test kits measuring the tumor HRD status is needed. To date, various assys has been developed to measure the HRD status in tumor tissue based on different rationales and validations. In the present talk, not only an introduction of various kit assays but also central lab services will be discussed for their unique characters. Moreover, we will also discuss the recent findings further disclosed the biological of gynecology cancers leading to the development of potential biomarkers carrying prognostic and/or therapeutic relevance. Emerging integration of molecular profiling datasets has led to the identification of distinct molecular subtypes of gynecology cancers with diverse clinical behaviors and potential sensitivity to various therapies. It has also led to the disclosure of frequently altered genes and proteins that could lead to perturbation of intracellular signaling pathways and their clinical course.